News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Meet the 2024/2025 PCI Fellows Cohort
Eleven fellows were admitted to the 2023/2024 cohort out of a large application pool.
Penn’s Chief Innovation Officer John Swartley Interviewed by BioBuzz @ Philly Builds Bio+ Symposium and nominated for the Life Science Cares Leader of the Year Award
In the interview, Dr. Swartley talks about how he leads and supports innovation initiatives across Penn and his career in technology transfer.
Michael Kahana Featured in NY Post for Memory Research
Michael Kahana was recently featured in the New York Post for his cutting-edge research in memory recall.
Penn Engineering’s Shu Yang to Co-Design Artificial Reef Structures that Help Harness Wave Energy
Dr. Yang’s focus is developing low-cost and recycled carbonated materials that are safe for, and tolerant of, the marine environment.
Jay Z’s Shawn Carter Foundation in Collaboration with Coalition for Equity and Opportunity at Penn’s Wharton School, Launch ‘Champions for Financial Legacy’ Program for HBCUs
This partnership focuses on transforming Dr. Weigelt's community program, "Bridges to Wealth," into a broader initiative called "Champions for Financial Legacy."
Mitchell Lab Discovers Siloxane-Enhanced Nanoparticles and Refines LNPs to Advance mRNA Medicine
A group of researchers at Penn Engineering led by Michael Mitchell, PhD, Associate Professor in Bioengineering, have developed a method to direct lipid nanoparticles (LNPs) to target specific tissues.
Franklin Biolabs Names its First CEO
Franklin Biolabs, a Penn spinout founded by James Wilson, MD, PhD, Rose H. Weiss Professor in Penn Medicine, has named Vatsala Naageshwaran as its first chief executive officer.
Ocuphire Pharma Announces Acquisition of Opus Genetics, a Penn startup based on technology developed by Dr. Jean Bennett and colleagues
The merger between Opus and Ocuphire creates a transformative biotech company, renamed Opus Genetics, Inc, which is committed to the development of gene therapies for the treatment of IRDs.
EpiVario Secures Key Patents for Innovative Addiction Treatment
EpiVario, Inc., a Penn spinout co-founded by Shelley Berger, PhD, the Daniel S. Och University Professor at Penn Medicine, announced the issuance to Penn of US Patent No. 12,077,527.
Penn spinout REGENXBIO Presents Positive Data from Phase II Study for Wet AMD Treatment
Penn spinout REGENXBIO, co-founded by James Wilson, MD, PhD, Rose H. Weiss Professor in Penn Medicine, announced positive results from a phase II study for its treatment ABBV-RGX-314.